News

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new…

2 days ago

Central Georgia Cancer Care Joins American Oncology Network to Elevate Local Cancer Care Delivery

Central Georgia Cancer Care Joins American Oncology Network to Elevate Local Cancer Care Delivery From left to right: Bradley T.…

2 days ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent…

2 days ago

AlzeCure Pharma Publishes its Annual Report for 2023

STOCKHOLM, SE / ACCESSWIRE / April 4, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical…

3 days ago

World Hepatitis Summit 2024 Convenes in Lisbon

The World Hepatitis Summit (WHS) 2024 Will Bring Together Global Experts to Discuss the Latest Advances in Hepatitis Prevention, Diagnosis…

3 days ago

American College of Osteopathic Family Physicians Announces 2024-2025 Board of Governors

CHICAGO, IL / ACCESSWIRE / April 3, 2024 / The American College of Osteopathic Family Physicians (ACOFP) announces its new…

3 days ago

ACOFP Foundation Announces New Campaign, Family Medicine Forward

Campaign underscores the urgency and need to support early career osteopathic family physicians.CHICAGO, IL / ACCESSWIRE / April 3, 2024…

3 days ago

Reveal Lasers Reports First Quarter With Record-Breaking 300% Growth

LAS VEGAS, NV / ACCESSWIRE / April 3, 2024 / Reveal Lasers, a burgeoning force in the aesthetics industry, proudly…

3 days ago

Weave Enhances Integration with DrChrono by EverHealth

Deeper integration unlocks powerful Weave features to improve patient experiencesLEHI, Utah--(BUSINESS WIRE)--Weave (NYSE: WEAV), a leading all-in-one experience platform for…

3 days ago

Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature

CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human,…

3 days ago